Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 230

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 230
---

scientific operations were conducted with more consulting and fewer employees in the three-month period ended September 30, 2024, versus
the three-month period ended September 30, 2023. The remaining $0.1 million increase in the three-month period ended September 30, 2024,
over the three-month period ended September 30, 2023, was related to lab supplies and expenses, additional pre-clinical work and facilities
rent escalation.

The Company anticipates
that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted
services for preclinical and clinical development of its product candidates, as well as for manufacturing of product to be used in clinical
development.

Other Income

Other income was $0.2 million
for the three-month period ended September 30, 2024 and 2023. The immaterial change was related to higher interest income and slightly
lower gain from revaluation of liabilities in the three-month period ended September 30, 2024, versus the three-month period ended September
30, 2023.

<div align='center'>134</div>

Results of Operations for the nine-months ended September 30, 2024 and 2023

The Results of Operations
for the nine-month period ended September 30, 2024 are pro forma as the period presented in the following table and discussion
includes the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14,
2024 through September 30, 2024. This pro forma period from January 1, 2024 to September 30, 2024 does not include the Merger transactions
that occurred on-the-line.

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

Condensed ConsolidatedSTATEMENTS OF OPERATIONS

(Unaudited)</div>

| Operating expenses:                             |     | For the nine months ended         
 September 30,                     
 2024                              
 (Pro                              
 forma, Predecessor and Successor) |             |   |     | 2023          
 (Predecessor) |            |   |     | Difference |            |   |
|:------------------------------------------------|:----|:----------------------------------|------------:|:--|:----|:--------------|-----------:|:--|:----|:-----------|-----------:|:--|
| Research